Thiotepa is an alkylating agent that has b e e n widely used in a variety of lymphohematopoietic diseases, including pretreatment for allogeneic hematopoietic stem cell transplantation, pretreatment for autologous hematopoietic stem cell transplantation, primary central nervous system lymphoma and chemotherapy for lymphohematopoietic diseases. However, thiotepa was re-listed in China until 2019, and most physicians has little clinical experience on the use of this agent. Based on the results of the clinical application of thiotepa in China, and the reports in the relevant domestic and foreign literature, the Chinese hematology and oncology experts developed the Chinese expert consensus on the clinical application of thiotepa in hematological and lymphatic system tumors and hematopoietic stem cell transplantation.